-transparent.png){kind=logo}
In one form of beta-thalassemia, a genetic blood disorder, a mutation in intron 2 of the beta-globin gene (IVS2-654) causes aberrant splicing of beta-globin pre-mRNA and, consequently, beta-globin deficiency. Treatment of mammalian cells stably expressing the IVS2-654 human beta-globin gene with antisense oligonucleotides targeted at the aberrant splice sites restored correct splicing in a dose-dependent fashion, generating correct human beta-globin mRNA and polypeptide. Both products persisted for up to 72 hr posttreatment. The oligonucleotides modified splicing by a true antisense mechanism without overt unspecific effects on cell growth and splicing of other pre-mRNAs. This novel approach in which antisense oligonucleotides are used to restore rather than to down-regulate the activity of the target gene is applicable to other splicing mutants and is of potential clinical interest.
H Sierakowska, and
M J Sambade, and
S Agrawal, and
R Kole
September 2002,
Molecular pharmacology,
H Sierakowska, and
M J Sambade, and
S Agrawal, and
R Kole
September 1993,
Proceedings of the National Academy of Sciences of the United States of America,
H Sierakowska, and
M J Sambade, and
S Agrawal, and
R Kole
February 2018,
Cold Spring Harbor protocols,
H Sierakowska, and
M J Sambade, and
S Agrawal, and
R Kole
November 2000,
The Journal of biological chemistry,
H Sierakowska, and
M J Sambade, and
S Agrawal, and
R Kole
November 1997,
Zhonghua yi xue za zhi,
H Sierakowska, and
M J Sambade, and
S Agrawal, and
R Kole
January 2018,
Methods in molecular biology (Clifton, N.J.),
H Sierakowska, and
M J Sambade, and
S Agrawal, and
R Kole
January 1997,
Acta biochimica Polonica,
H Sierakowska, and
M J Sambade, and
S Agrawal, and
R Kole
March 1999,
Current opinion in drug discovery & development,
H Sierakowska, and
M J Sambade, and
S Agrawal, and
R Kole
January 2001,
BMC biochemistry,
H Sierakowska, and
M J Sambade, and
S Agrawal, and
R Kole
September 1988,
The Journal of clinical investigation,
